Anzeige
Mehr »
Lynx Broker
Login
Sonntag, 17.11.2019 Börsentäglich über 12.000 News von 617 internationalen Medien
Millionenauftrag für Microcap! Entsprechende Reaktion am Montag erwartet…
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Business Review

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
FrUS FDA accepts regulatory submission for Selumetinib
FrEpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform
FrShionogi gets FDA approval for cUTI drug Fetroja
DoGSK's mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome
DoFinch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics
DoRDD Pharma signs LOI to acquire Naia Rare Diseases
DoMerck to acquire Calporta Therapeutics for $576m
MiLupin to sell its stake in Kyowa to Unison for $526m
MiMylan, Pfizer announce Viatris as new company name
MiX4 Pharmaceuticals receives breakthrough therapy designation from FDA for Mavorixafor to treat WHIM Syndrome
MiBoehringer, Eli Lilly begin sixth phase III study for Jardiance in heart failure
DiRoche's risdiplam meets primary endpoint in phase 3 SMA trial
DiNEC and VAXIMM announce collaboration to advance personalized neoantigen cancer vaccines
DiNovartis' Sandoz to buy Aspen's Japanese business in $441m deal
DiATAI Life Sciences and Cyclica launch joint venture to revolutionise drug development for mental health disorders
MoStone Capital Partners Biosyngen to setup $50m biopharmaceutical investment fund in Singapore
MoAbbVie submits sNDA to FDA for IMBRUVICA, Rituximab combo for CLL
MoFDA approves Reblozyl for treatment of anaemia in beta thalassemia
08.11.Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials
08.11.Johnson & Johnson seeks EMA approval for Ebola vaccine regimen
08.11.Takeda's dengue vaccine candidate demonstrates protection in children ages four to 16 years
07.11.Samsung Bioepis enters into commercialisation agreement for next-generation biosimilar candidates
07.11.Axcella achieves initial milestones with its hematology product candidate AXA4010
07.11.Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments
06.11.Cyclica collaborates with Enamine to use REAL technology in its ligand design platform for AI-augmented drug design